What is PROCEPT BioRobotics?
Headquartered in San Jose, California, PROCEPT BioRobotics is a commercial-stage medical technology firm specializing in the development of transformative urological solutions. The company's core innovation, the AquaBeam Robotic System, integrates real-time multidimensional imaging with automated robotics to perform waterjet ablation for prostate tissue removal. This technology is engineered to provide consistent, durable clinical outcomes that are largely independent of surgeon experience or anatomical variability. As a key player in the minimally invasive surgery market, PROCEPT BioRobotics is redefining the standard of care for BPH, a condition affecting millions of men globally. The firm's focus on precision, safety, and efficiency has positioned it as a disruptive force within the broader surgical robotics landscape.
How much funding has PROCEPT BioRobotics raised?
PROCEPT BioRobotics has raised a total of $601.3M across 10 funding rounds:
Series C
$6M
Debt
$7.7M
Series A
$7.7M
Series D
$42M
Series B
$42M
Series E
$118M
Series F
$77M
Series G
$85M
Share Placement
$163.9M
Debt
$52M
Series C (2013): $6M, investors not publicly disclosed
Debt (2014): $7.7M, investors not publicly disclosed
Series A (2014): $7.7M, investors not publicly disclosed
Series D (2015): $42M featuring Novo A/S
Series B (2015): $42M backed by Novo Holdings
Series E (2018): $118M with participation from Perceptive Advisors, Viking Global Investors, and CPMG
Series F (2020): $77M, investors not publicly disclosed
Series G (2021): $85M supported by Viking Global Investors, Duquesne Family Office, T. Rowe Price, Perceptive Advisors, Fidelity, and CPMG
Share Placement (2021): $163.9M, investors not publicly disclosed
Debt (2022): $52M backed by CIBC Innovation Banking
Key Investors in PROCEPT BioRobotics
Viking Global Investors
A global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across diverse industries.
Perceptive Advisors
An investment firm managing significant assets with a dedicated focus on funding innovative healthcare and life sciences technologies.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term value creation in the life sciences sector.
What's next for PROCEPT BioRobotics?
With the support of its recent capital influx, PROCEPT BioRobotics is well-positioned to accelerate its commercial penetration and further refine its robotic platform. The strategic focus moving forward involves scaling the adoption of its image-guided systems across major healthcare networks and investing in long-term clinical data to further validate the durability of its waterjet ablation therapy. As the company continues to navigate the complexities of the urology market, the emphasis will remain on operational excellence and the expansion of its intellectual property portfolio. By maintaining a robust balance sheet and leveraging its established institutional partnerships, PROCEPT BioRobotics is poised to sustain its growth momentum and solidify its leadership in the surgical robotics domain.
See full PROCEPT BioRobotics company page
